Symbols / RDHL Stock $1.01 -0.98% RedHill Biopharma Ltd.

Healthcare • Drug Manufacturers - Specialty & Generic • Israel • NCM
RDHL (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Mr. Dror Ben-Asher
Exch · Country NCM · Israel
Market Cap 5.24M
Enterprise Value —
Income -8.08M
Sales 286.00K
FCF (ttm) -3.53M
Book/sh -2.45
Cash/sh 3,971,000.00
Employees —
Insider 10d —
IPO Jan 07, 2013
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E inf
Forward P/E 33.67
PEG —
P/S 18.33
P/B -0.41
P/C —
EV/EBITDA —
EV/Sales —
Quick Ratio 0.21
Current Ratio 0.34
Debt/Eq 25.07
LT Debt/Eq —
EPS (ttm) 0.00
EPS next Y 0.03
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2023-04-28
Earnings (prior) 2023-04-28
ROA -22.79%
ROE —
ROIC —
Gross Margin 100.00%
Oper. Margin -27.65%
Profit Margin -150.00%
Shs Outstand 5.19M
Shs Float —
Insider Own 0.00%
Instit Own 9.70%
Short Float 0.15%
Short Ratio 0.34
Short Interest 7.16K
52W High 3.31
vs 52W High -69.49%
52W Low 0.71
vs 52W Low 42.25%
Beta —
Impl. Vol. —
Rel Volume 0.71
Avg Volume 39.46K
Volume 28.19K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $1.02
Price $1.01
Change -0.98%
About

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$1.01
Latest analyst target
3. DCF / Fair value
$-12.24
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.01
Low
—
High
—
Mean
—
News
RSS: Latest RDHL news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-06 RADAY GILEAD Chief Operating Officer — 15,740,000 $0.83 $13,050,034
2026-04-06 RADAY GILEAD Chief Operating Officer — 30,780,000 $0.83 $25,519,698
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.29
0.00
0.00
-100.00%
61.80
Operating Revenue
0.29
0.00
0.00
-100.00%
61.80
Cost Of Revenue
—
3.19
-7.72%
3.46
-89.62%
33.34
Reconciled Cost Of Revenue
—
3.19
-7.72%
3.46
-89.62%
33.34
Gross Profit
—
4.85
+57.96%
3.07
-89.21%
28.46
Operating Expense
8.20
+26.56%
6.47
-32.18%
9.55
-86.61%
71.31
Research And Development
2.02
+27.39%
1.59
-55.00%
3.53
-51.52%
7.28
Selling General And Administration
6.17
+26.29%
4.89
-18.79%
6.02
-90.60%
64.03
Selling And Marketing Expense
—
1.00
-52.17%
2.10
-76.87%
9.06
General And Administrative Expense
6.17
+26.29%
4.89
-18.79%
6.02
-89.05%
54.97
Salaries And Wages
2.28
+0.66%
2.27
-26.98%
3.10
-90.95%
34.28
Other Gand A
3.89
+48.44%
2.62
-10.08%
2.92
-85.91%
20.69
Other Operating Expenses
—
—
-44.06
—
Total Expenses
8.20
+26.56%
6.47
-32.18%
9.55
-90.88%
104.64
Operating Income
-7.91
-22.15%
-6.47
+32.18%
-9.55
+77.72%
-42.84
Total Operating Income As Reported
-7.94
-22.66%
-6.47
+32.18%
-9.55
+77.71%
-42.84
EBITDA
-7.65
-848.00%
1.02
+106.22%
-16.44
+25.87%
-22.18
Normalized EBITDA
-8.85
-22.27%
-7.23
+22.22%
-9.30
+73.85%
-35.56
Reconciled Depreciation
0.41
-33.93%
0.62
-68.89%
1.99
-75.59%
8.15
EBIT
-8.06
-2095.30%
0.40
+102.19%
-18.43
+39.23%
-30.34
Total Unusual Items
1.19
-85.55%
8.26
+215.60%
-7.14
-153.38%
13.38
Total Unusual Items Excluding Goodwill
1.19
-85.55%
8.26
+215.60%
-7.14
-153.38%
13.38
Special Income Charges
0.00
0.00
+100.00%
-1.46
0.00
Other Special Charges
—
2.36
+61.69%
1.46
—
Net Income
-0.43
+94.81%
-8.27
-134.57%
23.92
+133.37%
-71.67
Pretax Income
-8.08
-2344.44%
0.36
+101.95%
-18.50
+74.19%
-71.67
Net Non Operating Interest Income Expense
-1.33
+6.40%
-1.42
+21.31%
-1.81
+95.72%
-42.21
Interest Expense Non Operating
0.02
-56.82%
0.04
-30.16%
0.06
-99.85%
41.33
Net Interest Income
-1.33
+6.40%
-1.42
+21.31%
-1.81
+95.72%
-42.21
Interest Expense
0.02
-56.82%
0.04
-30.16%
0.06
-99.85%
41.33
Interest Income Non Operating
0.02
-70.89%
0.08
-13.19%
0.09
-35.00%
0.14
Interest Income
0.02
-70.89%
0.08
-13.19%
0.09
-35.00%
0.14
Other Income Expense
1.16
-85.95%
8.26
+215.60%
-7.14
-153.38%
13.38
Other Non Operating Income Expenses
—
—
8.60
—
Gain On Sale Of Security
1.19
-85.55%
8.26
+245.27%
-5.68
-142.47%
13.38
Gain On Sale Of Business
—
—
35.50
—
Tax Rate For Calcs
0.00
-100.00%
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
-100.00%
1.90
0.00
0.00
Net Income Including Noncontrolling Interests
-0.43
+94.81%
-8.27
-134.57%
23.92
+133.37%
-71.67
Net Income From Continuing Operation Net Minority Interest
-8.08
-2344.44%
0.36
+101.95%
-18.50
+74.19%
-71.67
Net Income From Continuing And Discontinued Operation
-0.43
+94.81%
-8.27
-134.57%
23.92
+133.37%
-71.67
Net Income Continuous Operations
-8.08
-2344.44%
0.36
+101.95%
-18.50
+74.19%
-71.67
Net Income Discontinuous Operations
7.65
+188.68%
-8.63
-120.34%
42.41
—
Normalized Income
-9.27
-54.60%
-6.00
+47.18%
-11.36
+86.65%
-85.05
Net Income Common Stockholders
-0.43
+94.81%
-8.27
-134.57%
23.92
+133.37%
-71.67
Diluted EPS
—
0.00
-100.00%
100.00
+108.33%
-1,200.00
Basic EPS
—
—
100.00
+108.33%
-1,200.00
Basic Average Shares
—
1.23
+375.56%
0.26
+320.45%
0.06
Diluted Average Shares
—
1.23
+375.56%
0.26
+320.45%
0.06
Diluted NI Availto Com Stockholders
-0.43
+94.81%
-8.27
-134.57%
23.92
+133.37%
-71.67
Earnings From Equity Interest
-0.03
0.00
0.00
—
Total Other Finance Cost
1.33
-8.37%
1.46
-20.60%
1.83
+80.97%
1.01
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
25.34
+40.47%
18.04
-21.71%
23.05
-85.49%
158.87
Current Assets
6.53
-45.19%
11.91
-26.20%
16.14
-81.21%
85.90
Cash Cash Equivalents And Short Term Investments
3.97
-13.99%
4.62
-17.09%
5.57
-72.13%
19.98
Cash And Cash Equivalents
3.97
-13.99%
4.62
-17.09%
5.57
-72.11%
19.97
Cash Equivalents
2.62
-4.10%
2.73
0.00
-100.00%
6.64
Cash Financial
1.35
-28.37%
1.88
-66.21%
5.57
-58.20%
13.32
Other Short Term Investments
—
—
0.00
-100.00%
0.01
Receivables
2.48
-30.48%
3.57
-12.64%
4.08
-89.22%
37.88
Accounts Receivable
0.08
-96.89%
2.54
-2.01%
2.59
-92.49%
34.52
Other Receivables
2.40
+133.69%
1.03
-31.12%
1.49
-55.55%
3.35
Inventory
0.00
-100.00%
3.65
-16.81%
4.39
-60.13%
11.01
Raw Materials
0.00
-100.00%
0.51
-38.04%
0.83
-53.92%
1.80
Work In Process
0.00
-100.00%
0.31
+32.19%
0.23
-90.23%
2.38
Finished Goods
0.00
-100.00%
2.83
-14.96%
3.33
-51.25%
6.83
Prepaid Assets
0.08
+1.30%
0.08
-94.12%
1.31
+26.82%
1.03
Restricted Cash
—
0.00
-100.00%
0.79
-95.06%
16.00
Total Non Current Assets
18.82
+206.87%
6.13
-11.22%
6.91
-90.53%
72.97
Net PPE
1.10
+152.86%
0.44
-63.03%
1.18
-83.57%
7.19
Gross PPE
2.51
+43.45%
1.75
-27.94%
2.43
-70.65%
8.27
Accumulated Depreciation
-1.40
-7.01%
-1.31
-5.38%
-1.25
-15.71%
-1.08
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
1.07
+0.47%
1.07
-16.24%
1.27
-43.61%
2.26
Other Properties
—
—
—
5.63
Leases
1.44
+110.87%
0.68
-40.89%
1.15
-80.83%
6.01
Goodwill And Other Intangible Assets
5.29
-4.62%
5.55
-0.56%
5.58
-91.50%
65.63
Other Intangible Assets
5.29
-4.62%
5.55
-0.56%
5.58
-91.50%
65.63
Investments And Advances
12.05
0.00
—
—
Long Term Equity Investment
12.05
0.00
—
—
Non Current Accounts Receivable
0.20
—
—
—
Other Non Current Assets
0.17
+14.86%
0.15
+0.68%
0.15
-2.00%
0.15
Total Liabilities Net Minority Interest
21.08
-7.26%
22.73
+8.33%
20.98
-89.88%
207.27
Current Liabilities
19.22
-13.51%
22.22
+11.21%
19.98
-89.88%
197.45
Payables And Accrued Expenses
10.02
-0.32%
10.06
+42.78%
7.04
-77.68%
31.55
Payables
6.42
-18.38%
7.86
+139.81%
3.28
-78.70%
15.39
Accounts Payable
6.42
-18.38%
7.86
+139.81%
3.28
-22.51%
4.23
Other Payable
—
—
—
11.16
Current Accrued Expenses
3.61
+64.37%
2.19
-41.70%
3.77
-76.71%
16.17
Pensionand Other Post Retirement Benefit Plans Current
0.54
+6.47%
0.51
-29.85%
0.73
-56.39%
1.67
Current Debt And Capital Lease Obligation
0.17
-51.84%
0.35
-50.84%
0.72
-99.38%
116.25
Current Debt
—
—
—
115.22
Other Current Borrowings
—
—
—
115.22
Current Capital Lease Obligation
0.17
-51.84%
0.35
-50.84%
0.72
-30.43%
1.03
Other Current Liabilities
2.18
+8.13%
2.02
+139.71%
0.84
+637.72%
0.11
Total Non Current Liabilities Net Minority Interest
1.86
+268.99%
0.50
-49.45%
0.99
-89.86%
9.82
Long Term Debt And Capital Lease Obligation
0.90
+29900.00%
0.00
-99.34%
0.46
-92.94%
6.44
Long Term Debt
—
—
—
—
Long Term Capital Lease Obligation
0.90
+29900.00%
0.00
-99.34%
0.46
-92.94%
6.44
Tradeand Other Payables Non Current
—
—
—
0.00
Other Non Current Liabilities
0.96
+91.20%
0.50
-7.41%
0.54
-28.00%
0.75
Stockholders Equity
4.27
+191.14%
-4.68
-326.34%
2.07
+104.27%
-48.40
Common Stock Equity
4.27
+191.14%
-4.68
-326.34%
2.07
+104.27%
-48.40
Capital Stock
147.64
+321.40%
35.04
+63.41%
21.44
+656.30%
2.83
Common Stock
147.64
+321.40%
35.04
+63.41%
21.44
+656.30%
2.83
Share Issued
50,923.26
+292.12%
12,986.62
+65.02%
7,869.85
+744.44%
931.96
Ordinary Shares Number
50,923.26
+292.12%
12,986.62
+65.02%
7,869.85
+744.44%
931.96
Additional Paid In Capital
270.38
-27.91%
375.08
-3.42%
388.36
+1.50%
382.62
Retained Earnings
-413.75
+0.25%
-414.80
-1.73%
-407.74
+6.02%
-433.86
Total Equity Gross Minority Interest
4.27
+191.14%
-4.68
-326.34%
2.07
+104.27%
-48.40
Total Capitalization
4.27
+191.14%
-4.68
-326.34%
2.07
+104.27%
-48.40
Working Capital
-12.69
-23.09%
-10.31
-168.33%
-3.84
+96.56%
-111.55
Invested Capital
4.27
+191.14%
-4.68
-326.34%
2.07
-96.90%
66.82
Total Debt
1.07
+200.56%
0.36
-69.65%
1.17
-99.04%
122.69
Net Debt
—
—
—
95.25
Capital Lease Obligations
1.07
+200.56%
0.36
-69.65%
1.17
-84.31%
7.47
Net Tangible Assets
-1.02
+90.00%
-10.23
-191.54%
-3.51
+96.92%
-114.03
Tangible Book Value
-1.02
+90.00%
-10.23
-191.54%
-3.51
+96.92%
-114.03
Current Provisions
6.30
-32.13%
9.29
-12.82%
10.65
-77.74%
47.87
Derivative Product Liabilities
—
—
0.74
-71.75%
2.62
Investmentsin Joint Venturesat Cost
12.05
0.00
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-9.65
-3.01%
-9.37
+73.84%
-35.82
-22.73%
-29.18
Cash Flow From Continuing Operating Activities
-9.65
-3.01%
-9.37
+73.84%
-35.82
-22.73%
-29.18
Net Income From Continuing Operations
-0.43
+94.81%
-8.27
-134.57%
23.92
+133.37%
-71.67
Depreciation Amortization Depletion
0.41
-33.93%
0.62
-68.89%
1.99
-75.59%
8.15
Depreciation
0.38
-34.69%
0.59
-59.31%
1.45
-32.35%
2.14
Amortization Cash Flow
0.03
-19.35%
0.03
-94.31%
0.55
-90.94%
6.02
Depreciation And Amortization
0.41
-33.93%
0.62
-68.89%
1.99
-75.59%
8.15
Amortization Of Intangibles
0.03
-19.35%
0.03
-94.31%
0.55
-90.94%
6.02
Other Non Cash Items
—
2.34
+530.39%
-0.54
-101.64%
33.15
Stock Based Compensation
0.46
-31.28%
0.67
-59.62%
1.65
-70.98%
5.67
Operating Gains Losses
-8.12
-19.84%
-6.78
+85.65%
-47.21
-277.57%
-12.50
Gain Loss On Investment Securities
-0.26
+96.13%
-6.77
-176.49%
8.85
+171.02%
-12.46
Unrealized Gain Loss On Investment Securities
—
—
—
0.00
Net Foreign Currency Exchange Gain Loss
0.09
+2425.00%
-0.00
-121.05%
0.02
+147.50%
-0.04
Change In Working Capital
-1.97
-195.91%
2.05
+113.14%
-15.62
-295.04%
8.01
Change In Receivables
2.26
+4244.23%
0.05
-99.84%
31.93
+1222.32%
-2.85
Changes In Account Receivables
2.26
+4244.23%
0.05
-99.84%
31.93
+1222.32%
-2.85
Change In Inventory
-0.38
-150.81%
0.74
-69.08%
2.39
-37.20%
3.80
Change In Prepaid Assets
-2.91
-271.54%
1.70
+7.00%
1.59
+478.83%
0.27
Change In Payables And Accrued Expense
2.04
+119.10%
0.93
+106.51%
-14.31
-37.81%
-10.38
Change In Accrued Expense
2.48
-18.51%
3.04
+122.78%
-13.35
-353.14%
-2.95
Change In Payable
-0.44
+79.29%
-2.11
-121.64%
-0.95
+87.19%
-7.43
Change In Account Payable
-0.44
+79.29%
-2.11
-121.64%
-0.95
+87.19%
-7.43
Change In Other Working Capital
-2.98
-118.45%
-1.37
+96.33%
-37.22
-316.89%
17.16
Investing Cash Flow
1.69
+18888.89%
-0.01
-325.00%
0.00
-99.95%
8.30
Cash Flow From Continuing Investing Activities
1.69
+18888.89%
-0.01
-325.00%
0.00
-99.95%
8.30
Net PPE Purchase And Sale
-0.01
+44.44%
-0.01
+18.18%
-0.01
+94.44%
-0.20
Purchase Of PPE
-0.01
+44.44%
-0.01
+18.18%
-0.01
+94.44%
-0.20
Capital Expenditure
-0.01
+44.44%
-0.01
+18.18%
-0.01
+94.44%
-0.20
Net Investment Purchase And Sale
0.00
0.00
-100.00%
0.01
-99.82%
8.50
Purchase Of Investment
—
—
—
—
Sale Of Investment
—
—
0.01
-99.82%
8.50
Net Business Purchase And Sale
2.00
0.00
0.00
—
Gain Loss On Sale Of Business
-7.98
0.00
+100.00%
-56.08
0.00
Net Intangibles Purchase And Sale
—
—
—
0.00
Purchase Of Intangibles
—
—
—
0.00
Net Other Investing Changes
-0.30
—
—
—
Financing Cash Flow
7.32
-13.07%
8.42
-60.74%
21.44
+87.19%
11.45
Cash Flow From Continuing Financing Activities
7.32
-13.07%
8.42
-60.74%
21.44
+87.19%
11.45
Net Issuance Payments Of Debt
-0.45
+29.72%
-0.64
+45.87%
-1.18
+20.34%
-1.48
Issuance Of Debt
—
—
—
0.00
Repayment Of Debt
-0.45
+29.72%
-0.64
+45.87%
-1.18
+20.34%
-1.48
Long Term Debt Issuance
—
—
—
0.00
Long Term Debt Payments
-0.45
+29.72%
-0.64
+45.87%
-1.18
+20.34%
-1.48
Net Long Term Debt Issuance
-0.45
+29.72%
-0.64
+45.87%
-1.18
+20.34%
-1.48
Net Common Stock Issuance
7.76
-6.04%
8.26
-40.81%
13.96
-41.36%
23.81
Proceeds From Stock Option Exercised
—
—
0.00
0.00
Net Other Financing Charges
—
0.79
-90.87%
8.65
+179.56%
-10.88
Changes In Cash
-0.64
+32.99%
-0.96
+93.32%
-14.38
-52.46%
-9.43
Effect Of Exchange Rate Changes
-0.00
-122.22%
0.01
+140.91%
-0.02
+71.05%
-0.08
Beginning Cash Position
4.62
-17.09%
5.57
-72.11%
19.97
-32.25%
29.47
End Cash Position
3.97
-13.99%
4.62
-17.09%
5.57
-72.11%
19.97
Free Cash Flow
-9.66
-2.96%
-9.38
+73.83%
-35.83
-21.94%
-29.38
Interest Paid Supplemental Data
0.02
-67.27%
0.06
-85.01%
0.37
-95.51%
8.18
Common Stock Issuance
7.76
-6.04%
8.26
-40.81%
13.96
-41.36%
23.81
Earnings Losses From Equity Investments
0.03
0.00
0.00
—
Issuance Of Capital Stock
7.76
-6.04%
8.26
-40.81%
13.96
-41.36%
23.81
Sale Of Business
2.00
0.00
0.00
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category